

EAU GUIDELINES ON UROTHELIAL CARCINOMA OF THE UPPER URINARY TRACT (UTUCs)

(Text update March 2020)

M. Rouprêt, M. Babjuk, M. Burger, E. Compérat, N.C. Cowan, P. Gontero, A.H. Mostafid, J. Palou, B.W.G. van Rhijn, S.F. Shariat, R. Sylvester, R. Zigeuner
Guidelines Associates: O. Capoun, D. Cohen, J.L. Dominguez-Escrig, B. Peyronnet, T. Seisen, V. Soukup

Epidemiology

Upper urinary tract urothelial carcinomas (UTUCs) are uncommon and account for only 5-10% of urothelial carcinomas (UCs). They have a similar morphology to bladder carcinomas and nearly all UTUCs are urothelial in origin.

Recommendations	Strength rating
Evaluate patient and family history based on the Amsterdam criteria to identify patients with upper tract urothelial carcinoma.	Weak
Evaluate patient exposure to smoking and aristolochic acid.	Weak

Staging and grading systems

The UICC 2017 TNM (Tumour, Node, Metastasis Classification) for renal pelvis and ureter is used for staging (Table 1).

Tumour grade

The 2004/2016 WHO classification distinguishes between non-invasive tumours:

- papillary urothelial neoplasia of low malignant potential;
- low-grade urothelial carcinomas;
- high-grade urothelial carcinomas.

As well as flat lesions (carcinoma *in situ*) and invasive carcinoma.

Upper urinary tract tumours with low malignant potential are very rare.

Table 1: TNM Classification 2017

T - Primary tumour	
TX	Primary tumour cannot be assessed
T0	No evidence of primary tumour
Ta	Non-invasive papillary carcinoma
Tis	Carcinoma <i>in situ</i>
T1	Tumour invades subepithelial connective tissue
T2	Tumour invades muscularis
T3	(Renal pelvis) Tumour invades beyond muscularis into peripelvic fat or renal parenchyma (Ureter) Tumour invades beyond muscularis into periureteric fat
T4	Tumour invades adjacent organs or through the kidney into perinephric fat
N - Regional lymph nodes	
NX	Regional lymph nodes cannot be assessed
N0	No regional lymph node metastasis
N1	Metastasis in a single lymph node 2 cm or less in greatest dimension

N2	Metastasis in a single lymph node more than 2 cm, or multiple lymph nodes
M - Distant metastasis	
M0	No distant metastasis
M1	Distant metastasis

Diagnosis


UTUCs are diagnosed using imaging, cystoscopy, urinary cytology and diagnostic ureteroscopy. In case conservative management is considered, a pre-operative ureteroscopic assessment is needed.

Recommendations	Strength rating
Perform a urethrocytoscopy to rule out bladder tumour.	Strong
Perform a computed tomography (CT) urography.	Strong
Use diagnostic ureteroscopy and biopsy if imaging and cytology are not sufficient for the diagnosis and/or risk-stratification of the tumour.	Strong
Magnetic resonance urography may be used when CT is contra-indicated.	Weak

Prognosis

Invasive UTUC usually have a very poor prognosis. The main prognostic factors are listed in Figure 1.

Figure 1: UTUC - prognostic factors




ASA = American Society of Anesthesiologists; BMI = body mass index; ECOG PS = Eastern Cooperative Oncology Group performance status; UTUC = upper urinary tract urothelial carcinoma.

Risk stratification

As tumour stage is difficult to assert clinically in UTUC, it is useful to “risk stratify” UTUC between low- and high-risk tumours to identify those patients who are more likely to benefit from kidney-sparing treatment (Figures 2 and 3).

Figure 2: Risk stratification of non-metastatic UTUC



*All of these factors need to be present.

** Any of these factors need to be present.

CTU = computed tomography urography; URS = ureteroscopy;
UTUC = upper urinary tract urothelial carcinoma.

Recommendation	Strength rating
Use pre-operative factors to risk-stratify patients for therapeutic guidance.	Weak

Disease management (see also Figures 3 & 4)

Localised disease

Kidney-sparing surgery

Kidney-sparing surgery for low-risk UTUC consists of surgery preserving the upper urinary renal unit and should be discussed in all low-risk cases, irrespective of the status of the contralateral kidney.

Kidney-sparing surgery potentially allows avoiding the morbidity associated with open radical surgery without compromising oncological outcomes and kidney function.

Kidney-sparing surgery can also be considered in select patients with serious renal insufficiency or solitary kidney (i.e. imperative indications).

Recommendations	Strength rating
Offer kidney-sparing management as primary treatment option to patients with low-risk tumours.	Strong
Offer kidney-sparing management to patients with high-risk tumours limited to the distal ureter.	Weak
Offer kidney-sparing management to patients with solitary kidney and/or impaired renal function, providing that it will not compromise survival. This decision will have to be made on a case-by-case basis with the patient.	Strong

The instillation of bacillus Calmette-Guérin or mitomycin C in the urinary tract by percutaneous nephrostomy, or via a ureteric stent is technically feasible after kidney-sparing management, or for treatment of carcinoma *in situ*. However, the benefits have not been confirmed.

High-risk non-metastatic disease

Radical nephroureterectomy

Open nephroureterectomy (RNU) with bladder cuff excision is the standard treatment for high-risk UTUC, regardless of tumour location.

Adjuvant chemotherapy after RNU reduces the risk of recurrence by more than 50% as compared to surgery alone. In high-risk patients, neoadjuvant chemotherapy has been associated with significant downstaging at surgery and ultimately survival benefit as compared to RNU alone.

Recommendations	Strength rating
Perform radical nephroureterectomy (RNU) in patients with high-risk non-metastatic upper tract urothelial carcinoma (UTUC).	Strong
Perform open RNU in non-organ confined UTUC.	Weak
Remove the bladder cuff in its entirety.	Strong
Perform a template-based lymphadenectomy in patients with muscle-invasive UTUC.	Strong
Offer peri-operative chemotherapy to patients with muscle-invasive UTUC.	Weak
Deliver a post-operative bladder instillation of chemotherapy to lower the intravesical recurrence rate.	Strong

Metastatic disease

Radical nephroureterectomy has no benefit in metastatic (M+) disease, but may be used in palliative care. As UTUCs are urothelial tumours, platinum-based chemotherapy should provide similar results to those in bladder cancer. Currently, insufficient data are available to provide any recommendations. Radiotherapy is no longer relevant nowadays, neither as a sole treatment option, nor as an adjunct to chemotherapy.

Recommendations	Strength rating
Offer radical nephroureterectomy as a palliative treatment to symptomatic patients with resectable locally advanced tumours.	Weak

First-line treatment for cisplatin-eligible patients	
Use cisplatin-containing combination chemotherapy with GC, MVAC, preferably with G-CSF, HD-MVAC with G-CSF or PCG.	Strong
Do not offer carboplatin and non-platinum combination chemotherapy.	Strong
First-line treatment in patients unfit for cisplatin	
Offer checkpoint inhibitors pembrolizumab or atezolizumab depending on PD-L1 status.	Weak
Offer carboplatin combination chemotherapy if PD-L1 is negative.	Strong
Second-line treatment	
Offer checkpoint inhibitor (pembrolizumab) to patients with disease progression during or after platinum-based combination chemotherapy for metastatic disease.	Strong
Offer checkpoint inhibitor (atezolizumab) to patients with disease progression during or after platinum-based combination chemotherapy for metastatic disease.	Strong
Only offer vinflunine to patients for metastatic disease as second-line treatment if immunotherapy or combination chemotherapy is not feasible. Alternatively, offer vinflunine as third- or subsequent-treatment line.	Strong

GC = gemcitabine plus cisplatin; G-CSF = granulocyte colony-stimulating factor; HD-MVAC = high-dose methotrexate, vinblastine, adriamycin plus cisplatin; PD-L1 = programmed death ligand 1; PCG = paclitaxel, cisplatin, gemcitabine.


Follow-up after initial treatment

In all cases, there should be strict follow-up after radical management to detect metachronous bladder tumours, as well as invasive tumours, local recurrence and distant metastases. When kidney-sparing surgery is performed, the ipsilateral upper urinary tract requires careful follow-up due to the high risk of recurrence.

Recommendations	Strength rating
After radical nephroureterectomy	
<i>Low-risk tumours</i>	
Perform cystoscopy at three months. If negative, perform subsequent cystoscopy nine months later and then yearly, for five years.	Weak
<i>High-risk tumours</i>	
Perform cystoscopy and urinary cytology at three months. If negative, repeat subsequent cystoscopy and cytology every three months for a period of two years, and every six months thereafter until five years, and then yearly.	Weak
Perform computed tomography (CT) urography and chest CT every six months for two years, and then yearly.	Weak
After kidney-sparing management	
<i>Low-risk tumours</i>	
Perform cystoscopy and CT urography at three and six months, and then yearly for five years.	Weak
Perform ureteroscopy (URS) at three months.	Weak

High-risk tumours	
Perform cystoscopy, urinary cytology, CT urography and chest CT at three and six months, and then yearly.	Weak
Perform URS and urinary cytology <i>in situ</i> at three and six months.	Weak

Figure 3: Proposed flowchart for the management of UTUC




* In patients with a solitary kidney, consider a more conservative approach.

CTU = computed tomography urography;

RNU = nephroureterectomy; UTUC = upper urinary tract urothelial carcinoma.

Figure 4: Surgical treatment according to location and risk status



1 = first treatment option; 2 = secondary treatment option.

*In case not amendable to endoscopic management.

LND = lymph node dissection; RNU = radical nephroureterectomy; URS = ureteroscopy;

UTUC = upper urinary tract urothelial carcinoma.



This short booklet text is based on the more comprehensive EAU Guidelines (ISBN 978-94-92671-07-3), available to all members of the European Association of Urology at their website: <http://www.uroweb.org/guidelines/>.